title: High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia.
authors.forename: Barbara
authors.initials: B
authors.lastname: Vannata
authors.forename: Idanna
authors.initials: I
authors.lastname: Innocenti
authors.forename: Francesco
authors.initials: F
authors.lastname: Autore
authors.forename: Federica
authors.initials: F
authors.lastname: Sorà
authors.forename: Patrizia
authors.initials: P
authors.lastname: Chiusolo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Leone
authors.forename: Simona
authors.initials: S
authors.lastname: Sica
authors.forename: Luca
authors.initials: L
authors.lastname: Laurenti
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy; D014740:Vidarabine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D000074323:Alemtuzumab; D014740:Vidarabine; C527517:ofatumumab; C024352:fludarabine